Immunic, Inc. financial data

Symbol
IMUX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1200 Avenue Of The Americas, Suite 200, New York, United States
State of incorporation
Delaware
Fiscal year end
December 31
Former names
VITAL THERAPIES INC (to 4/10/2019)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 358 % -47.8%
Debt-to-equity 39 % +135%
Return On Equity -170 % -28.1%
Return On Assets -122 % -7.44%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.1M shares +102%
Common Stock, Shares, Outstanding 90.1M shares +102%
Entity Public Float 110M USD +3.21%
Common Stock, Value, Issued 8K USD +100%
Weighted Average Number of Shares Outstanding, Basic 101M shares +128%
Weighted Average Number of Shares Outstanding, Diluted 101M shares +128%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 76.1M USD -6.47%
General and Administrative Expense 17.5M USD +14.1%
Operating Income (Loss) -93.6M USD +27.8%
Nonoperating Income (Expense) -1.66M USD -160%
Net Income (Loss) Attributable to Parent -95.3M USD +24.9%
Earnings Per Share, Basic -1.5 USD/shares +56.4%
Earnings Per Share, Diluted -1.5 USD/shares +56.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 79.7M USD +3.11%
Other Assets, Current 1.06M USD -23.9%
Assets, Current 85M USD -1.82%
Property, Plant and Equipment, Net 585K USD +102%
Operating Lease, Right-of-Use Asset 928K USD -50%
Goodwill 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 86.5M USD -2.53%
Accounts Payable, Current 7.89M USD +68%
Accrued Liabilities, Current 13.8M USD +9.21%
Liabilities, Current 22.7M USD +24.3%
Operating Lease, Liability, Noncurrent 241K USD -80.1%
Liabilities 22.9M USD +17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.78M USD -5.02%
Retained Earnings (Accumulated Deficit) -462M USD -26%
Stockholders' Equity Attributable to Parent 63.6M USD -8.24%
Liabilities and Equity 86.5M USD -2.53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24M USD -22.8%
Net Cash Provided by (Used in) Financing Activities 74.5M USD +145908%
Net Cash Provided by (Used in) Investing Activities -31K USD -101%
Common Stock, Shares Authorized 500M shares +285%
Common Stock, Shares, Issued 90.1M shares +102%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 79.7M USD +3.11%
Deferred Tax Assets, Valuation Allowance 99.1M USD +35.6%
Deferred Tax Assets, Gross 99.1M USD +35.6%
Operating Lease, Liability 955K USD -49.1%
Depreciation 31K USD +40.9%
Payments to Acquire Property, Plant, and Equipment 31K USD -70.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -95.5M USD +21.9%
Lessee, Operating Lease, Liability, to be Paid 1.02M USD -51.5%
Operating Lease, Liability, Current 714K USD +6.41%
Lessee, Operating Lease, Liability, to be Paid, Year Two 78K USD -84.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 433K USD -47.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 63K USD -71.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 82K USD -41.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 79K USD -45.1%
Additional Paid in Capital 522M USD +20.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 26K USD -18.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%